PDF(Pubmed)
Abstract：
Lorlatinib has been FDA-approved as a systemic therapy for ALK/ROS1-positive non-small cell lung cancer (NSCLC) patients. However, it has been associated with an increased frequency of neurocognitive adverse events (NAEs). Therefore, we conducted a systematic review and meta-analysis to assess the NAEs related to lorlatinib therapy in NSCLC patients. PubMed, Scopus, the Cochrane Library, and prominent conference proceedings were searched for eligible studies of lorlatinib in NSCLC patients. NAEs included cognitive, mood, speech, and psychotic effects. A total of 1147 patients from 12 studies were included; 62% had brain metastases. A pooled analysis of NAEs showed frequencies of cognitive effects of 14.57% (95% CI, 8.37 to 24.14, I2 = 84%), mood effects of 11.17% (95% CI, 5.93 to 20.07, I2 = 84%), speech effects of 7.24% (95% CI, 3.39 to 15.20, I2 = 72%), and psychotic effects of 4.97% (95% CI, 3.27 to 7.49, I2 = 21%). Clinical trials reported a significantly higher frequency of mood effects than was indicated by real-world data. These results highlight the importance of educating patients and healthcare professionals about lorlatinib-related NAEs for early detection and management to improve NSCLC patients\' quality of life.
摘要：
洛拉替尼已被FDA批准为ALK/ROS1阳性非小细胞肺癌（NSCLC）患者的全身性治疗。然而,它与神经认知不良事件(NAE)的发生频率增加有关.因此,我们进行了系统评价和荟萃分析,以评估NSCLC患者与氯拉替尼治疗相关的NAE.PubMed,Scopus,Cochrane图书馆,并在著名的会议记录中搜索了lorlatinib在NSCLC患者中的合格研究.NAE包括认知，心情,演讲,和精神病的影响。共纳入了来自12项研究的1147名患者；62%有脑转移。NAE的汇总分析显示，认知效应的频率为14.57％（95％CI，8.37至24.14，I2=84％），情绪影响11.17%（95%CI，5.93至20.07，I2=84%），言语效应为7.24%（95%CI，3.39至15.20，I2=72%），和4.97%的精神病效应（95%CI，3.27至7.49，I2=21%）。临床试验报告的情绪影响的频率明显高于现实世界的数据。这些结果突出了对患者和医疗保健专业人员进行关于氯拉替尼相关NAE的早期检测和管理以改善NSCLC患者生活质量的重要性。
